Current therapies for glioblastoma are not effective at stopping disease progression – particularly once the brain tumor recurs.
Every year, the American Brain Tumor Association (ABTA) brings together patients, caregivers, and survivors to learn about latest advances in brain tumor research, treatment, and care.
While various immunotherapies work through different mechanisms, they are all designed to enhance the immune system’s ability to recognize and target cancer cells. Pembrolizumab does so by binding and inhibiting PD-1, a protein that normally protects the body from attacking itself.
The newly released 2021 WHO Classification of Tumors of the Central Nervous System (CNS) introduces major changes that advance the role of molecular profiling in CNS tumor classification and includes ma